Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (November 2024)
89 slides from Immatics's investor presentation, Nov 18, 2024
Slide 1: Immatics Corporate Presentation November 18, 2024
Immatics Corporate Presentation November 18, 2024 Exhibit 99.4
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any of its affiliates, any of its or their respective c
Slide 3: Building a Leading TCR Therapeutics Company
Therapeutic Opportunity Potential for addressing large patient populations with high prevalence targets in solid tumors Two Clinical-Stage Modalities Pipeline of TCR-T and TCR Bispecific product candidates in clinical & preclinical development Building a Leading TCR Therapeutics Company Intro Differ
Slide 4: 2024 ACTengine and TCER Clinical Milestones
2024 ACTengine® and TCER® Clinical Milestones Targeted randomized Phase 3 trial for ACTengine® IMA203 in 2L+ melanoma in 2024 Clinical data update from Phase 1b dose expansion trial at SMR Conference on Oct 11, 2024; IMA203CD8 (GEN2) update at SITC Conference on Nov 9, 2024 ACTengine® IMA203 / IMA20
Slide 5: Two Distinct TCR-based Therapeutic Modalities in Clinical Development
Two Distinct TCR-based Therapeutic Modalities in Clinical Development Differentiated positioning of ACTengine® vs. TCER® based on patient population and medical need Intro 1 Interim data update from the ACTengine® IMA203 and IMA203CD8 monotherapies (published November 8, 2024) Autologous TCR-T (ACTe
Slide 6: Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics
Modality Product Candidate Target Preclinical Phase 1a1 Phase 1b1 Phase 2 Phase 3 Autologous ACT ACTengine® IMA203 PRAME ACTengine® IMA203CD8 PRAME ACTengine® IMA204 COL6A3 Autologous ACT Multiple programs Undisclosed ACTengine® IMA203 + mRNA cancer vaccine PRAME Allogeneic ACT γδ T cells ACTallo® I
Slide 7: Realizing the Full Multi-Cancer Opportunity of PRAME
Realizing the Full Multi-Cancer Opportunity of PRAME ACTengine® IMA203 (TCR-T) and TCER® IMA402 (TCR Bispecific) ACTengine® IMA203 (TCR-T) Cancer Cell Death PRAME is one of the most promising and most prevalent, clinically validated solid tumor targets known to date Leverage the full potential of ta
Slide 8: ACTengine IMA203 – TCR-T Targeting PRAME
ACTengine® IMA203 – TCR-T Targeting PRAME
Slide 9: The Multi-Cancer Opportunity of PRAME
The Multi-Cancer Opportunity of PRAME One of the Most Promising Solid Tumor Targets for TCR-based Therapies Known To Date High prevalence High target density Homogeneous expression “Clean” expression profile Clinical proof-of-concept sqNSCLC Ovarian Cancer PRAME fulfills all properties of an ideal t
Slide 10: IMA203 TCR-T Has the Potential to Reach a Large Patient Population
Selected Indications Incidence R/R Incidence PRAME Positive Patient Population Based on R/R Incidence; PRAME and HLA-A*02:01+ Cut. Melanoma 99,800 7,700 95% 2,999 Uveal Melanoma 1,500 800 89% 292 Ovarian Carcinoma 19,900 12,800 84% 4,408 Uterine Carcinoma 62,700 10,700 97% 4,255 Uterine Carcinosarco
Slide 11: ACTengine IMA203 Targeting PRAME – Mechanism of Action
ACTengine® IMA203 Targeting PRAME – Mechanism of Action Immatics’ Leading TCR-T Approach IMA203 LEUKAPHARESIS
Slide 12: ACTengine IMA203 TCR-T Product Manufacturing
ACTengine® IMA203 TCR-T Product Manufacturing Differentiated Manufacturing Process and Setup 1-week manufacturing process followed by 1-week QC release testing High manufacturing success rate of >95% to reach IMA203 target dose* Lean and cost-efficient process Proprietary Manufacturing Process IMA
Slide 13: ACTengine IMA203 TCR-T Monotherapy – Patient Flow
ACTengine® IMA203 TCR-T Monotherapy – Patient Flow HLA-A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow-up Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR-T Product Lymphodepletion* Target Profiling IMADetect® mRNA assa
Slide 14: ACTengine IMA203 TCR-T Trial in Melanoma
ACTengine® IMA203 TCR-T Trial in Melanoma Heavily Pretreated Patient Population Data cut-off Aug 23, 2024 1 See patient flow in appendix. 2 All infused patients; *Cutaneous melanoma patients had a median of 2 prior lines of checkpoints, see appendix; RP2D: recommended phase 2 dose; CPI: Checkpoint i
Slide 15: Most Frequent Adverse Events of IMA203 Across All Dose Levels
Data cut-off Aug 23, 2024 Most Frequent Adverse Events of IMA203 Across All Dose Levels in Phase 1a/b Most frequent adverse events were expected cytopenias (Grade 1-4) associated with lymphodepletion in all patients Mostly mild to moderate cytokine release syndrome (CRS) 37% (26/70) Grade 1 46% (32/
Slide 16: Tolerability Profile of IMA203 Across All Dose Levels
Tolerability Profile of IMA203 Across All Dose Levels in Phase 1a/b All ≥Grade 3 Adverse Events (N=701) All treatment-emergent adverse events (TEAEs) with ≥ Grade 3 regardless of relatedness to study treatment. Adverse events were coded using the Medical Dictionary for Regulatory Activities. Grades
Slide 17: Best Overall Response for IMA203 in Melanoma
Best Overall Response for IMA203 in Melanoma Objective Responses in Heavily Pretreated Patients in Phase 1b (N=28#) Data cut-off Aug 23, 2024 ongoing #First tumor assessment post infusion pending for two melanoma patients at data-cut; *Maximum change of target lesions and RECIST1.1 response at diffe
Slide 18: Response Over Time of IMA203 in Melanoma
Response Over Time of IMA203 in Melanoma Durable Responses 2 Years+ after Treatment in Heavily Pretreated Patients in Phase 1b (N=28#) Scans at approximately week 6, month 3 and then every 3 months Ongoing Data cut-off Aug 23, 2024 #First tumor assessment post infusion pending for two melanoma patie
Slide 19: Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion
Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion PFS of 6 Months and OS Not Reached in Melanoma Efficacy Population Progression Free Survival Data cut-off Aug 23, 2024 Overall Survival Overall survival (OS) and progression-free survival (PFS) censored at data-cut; * These dat
Slide 20: IMA203 Phase 1b in Melanoma: Overview of Studies
IMA203 Phase 1b in Melanoma: Overview of Studies PFS and OS Data in 2L+ Melanoma Cohorts Drug Product Phase N 2L+ melanoma patient population Prior lines of therapies mPFS (months) mOS (months) IMA203 in Melanoma 1b (Dose Expansion) 28 46% cutaneous 43% uveal 11% other 4% n=0, 18% n=1, 32% n=2, 29%
Slide 21: Enhanced PFS in Phase 1b Melanoma Patients with Deep Responses
Enhanced PFS in Phase 1b Melanoma Patients with Deep Responses N=26# Approx. half of all patients have a deep response (>50% tumor reduction) This subgroup of patients has highly medically meaningful mPFS of more than 1 year Patients with <50% tumor reduction (including tumor size increase) still ob
Slide 22: Dose Response Relationship
Dose Response Relationship IMA203 T Cell Dose is Associated with Clinical Activity and IMA203 T Cell Exposure (N=65 out of 68*) RP2D (n=23) (n=42) IMA203 T Cell Dose is Associated with Clinical Activity IMA203 T Cell Dose Correlates with T Cell Exposure 1Mann-Whitney U test, 2Spearman Correlation; *
Slide 23: Exposure Response Relationship
Exposure Response Relationship IMA203 T Cell Persistence Over Time and T Cell Exposure is Associated with Clinical Response IMA203 T cell exposure (Cmax & AUC (0-28d)) is associated with clinical responses Rapid T cell engraftment (Cmax) in all patients with over two years of persistence Higher Cmax
Slide 24: Patient Case A-DL4-03: Cutaneous Melanoma
Patient Case A-DL4-03 : Cutaneous Melanoma PET-based Complete Response 15 Months Post Infusion and Ongoing Response at 24 Months Images courtesy of treating physician (Dr. Martin Wermke, University of Dresden) 51-year-old male patient with complete remission according to PET imaging after 15 months
Slide 25: SUPRAME: Registration-enabling Randomized Phase 3 Trial
SUPRAME: Registration-enabling Randomized Phase 3 Trial Trial Design Following Recent Type D Meeting with FDA and SA Meeting with PEI1 ACTengine® IMA203 N=180 Investigator’s choice of selected approved treatments N=180 Endpoints Primary Endpoint PFS Secondary Endpoints Safety ORR + DOR No OS detrime
Slide 26: Combining TCR-T Therapy with Moderna's mRNA Cancer Vaccine – Patient Flow
Combining Immatics’ TCR-T Therapy with Moderna’s mRNA Cancer Vaccine – Patient Flow HLA-A*02 testing Blood sample; Central lab Treatment & Observation Phase (1 year) Follow-up (2 years) Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR-T Product Lymphodeplet
Slide 27: IMA203 TCR-T Monotherapy in Melanoma Summary of Clinical Data
ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME in Melanoma Summary of Clinical Data Tolerability Anti-Tumor Activity & Durability PFS & OS Biological Data Broad Reach Favorable tolerability profile: mostly mild to moderate CRS; infrequent ICANS (5.7% Gr1, 4.3% Gr2, 4.3% Gr3); no treatment relat
Slide 28: High Unmet Medical Need in Cutaneous and Uveal Melanoma
High Unmet Medical Need in Cutaneous and Uveal Melanoma Clinically and Commercially Attractive Features of IMA203 Cutaneous Melanoma Uveal Melanoma Patient Population 2L+ CPI-refractory, BRAF/MEK inhibitor-refractory if BRAF mutation+ 2L+ Kimmtrak-refractory, CPI/chemotherapy-refractory IMA203 Oppor
Slide 29: IMA203CD8 GEN2 – Leveraging CD8 and CD4 cells
IMA203CD8 GEN2 – IMA203 TCR-T Monotherapy Leveraging CD8 and CD4 cells Differentiated Pharmacology Compared to 1st-Generation TCR-only Approaches IMA203CD8 (GEN2) designed to broaden the clinical potential of IMA203 TCR-T monotherapy by adding functional CD4 T cells via co-transduction of CD8αβ alon
Slide 30: IMA203CD8 (GEN2) – Preclinical Assessment of Anti-Tumor Efficacy
IMA203CD8 (GEN2) – Preclinical Assessment of Anti-Tumor Efficacy Functional CD4 T cells Mediate Longer Anti-Tumor Activity than CD8 T cells in vitro 2nd addition of tumor cells 3rd 4th 5th 6th 2nd addition of tumor cells 3rd 4th 5th 6th IMA203CD8
Slide 31: IMA203CD8 (GEN2) – Overview of Patient Characteristics
IMA203CD8 (GEN2) – Overview of Patient Characteristics 1 DL4a cleared in Dec 2023; 2 DLTs at DL4b triggered modifications of the eligibility criteria, adapted patient population is treated with DL4c; 3 All patients who started lymphodepletion. 4 All infused patients with at least one tumor assessmen
Slide 32: Tolerability Data – IMA203CD8 (GEN2)
Tolerability Data – IMA203CD8 (GEN2) All ≥Grade 3 Adverse Events (N=44) Data cut-off Sep 30, 2024 IMA203CD8 Adverse event ≥ Grade 3 (System organ class, preferred term) No. % Patients with any adverse event 44 100.0 Adverse events of special interest 7 15.9 Cytokine release syndrome1 6 13.6 Immune e
Slide 33: IMA203CD8 (GEN2) – Best Overall Response in Dose Escalation
IMA203CD8 (GEN2) (N=41) – Best Overall Response in Dose Escalation Data cut-off Sep 30, 2024 Data cut-off Sep 30, 2024 IMA203CD8 cORR 41% (14/34) median DOR (min, max) mFU 9.2 months 2.0+, 23.5+ 13.1 months 10/17 responses ongoing including 3 confirmed responses at 1+ year Deep responses with ≥50% t
Slide 34: IMA203CD8 (GEN2) – Response over Time in Dose Escalation
IMA203CD8 (GEN2) (N=41) – Response over Time in Dose Escalation Data cut-off Sep 30, 2024 Data cut-off Sep 30, 2024 IMA203CD8 1 Metabolic CR according to PET-CT 2 Patients off study at data-cut; 3 three patients excluded from tumor shrinkage analysis and figures due to lack of post-treatment assessm
Slide 35: IMA203CD8 (GEN2): Translational Data Shows Enhanced Pharmacology
IMA203CD8 (GEN2): Translational Data Shows Enhanced Pharmacology IMA203 Phase 1b vs IMA203CD8 (GEN2) Trend towards responses at lower cell dose and higher tumor burden with IMA203CD8 Higher peak expansion (Cmax) of IMA203CD8 T cells when normalized to infused dose Higher activation levels in IMA203C
Slide 36: Opportunity of IMA203CD8 in Medium-Level PRAME Expressing Indications
Opportunity of IMA203CD8 in Medium-Level PRAME Expressing Indications * Patients treated at RP2D during Ph1b with evaluable post baseline assessments at data-cut off IMA203: Aug 23, 2024 IMA203CD8 PRAME expression level associates with clinical activity in IMA203 and IMA203CD8 treated patients Enhan
Slide 37: Patient Case DL4b-04: Synovial Sarcoma
Non-target Lesions Target Lesions Baseline Follow-up Month 12, -100% reduction 24-year-old male patient with complete remission according to PET imaging after 14 months post infusion 1 prior systemic treatment line: Doxorubicin + Ifosfamide + Mesna 3 years of cancer history At BL: 33.4 mm TL sum in
Slide 38: IMA203CD8 Summary of Clinical Data and Planned Next Steps
ACTengine® IMA203CD8 (GEN2) TCR-T Monotherapy Targeting PRAME Summary of IMA203CD8 Clinical Data and Planned Next Steps Data cut-off Sep 30, 2024 IMA203CD8 Manageable tolerability with most frequent ≥Grade 3 AEs being expected cytopenia DLTs in 2 patients at DL4b triggered dosing adjustment to DL4a
Slide 39: Potential of IMA203 in Additional Solid Cancer Indications
PRAME mRNA expression in IMA203 (GEN1) (n=14) Data cut-off Aug 23, 2024 PRAME mRNA expression in IMA203CD8 (GEN2) responders (n=13) Data cut-off Sep 30, 2024 Potential of IMA203 in Additional Solid Cancer Indications Based on PRAME Expression in IMA203 and IMA203CD8 (GEN2) Responders % PRAME-positiv
Slide 40: TCER — TCR Bispecifics
ooe immiatics TCER® — TCR Bispecifics
Slide 41: TCER – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics’ Next-generation, Half-Life Extended Bispecifics Proprietary TCER® Format Consisting of Three Distinct Elements High-affinity TCR domains targeting XPRESIDENT®-selected tumor-specific peptide-HLA molecules Low-affinity T cell recruiter against CD3/TCR Fc part for half-life extension
Slide 42: TCER – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics’ Next-generation, Half-Life Extended Bispecifics pHLA targeting TCR High-affinity (single digit nM) TCR targeting XPRESIDENT®-selected tumor-specific peptide-HLA molecules Broad therapeutic window through XPRESIDENT®-guided affinity maturation (>1000x)1 Complete tumor eradication in
Slide 43: Potency of Our Proprietary TCR Bispecific Format TCER
Potency of Our Proprietary TCR Bispecific Format TCER® Seven different TCR Bispecific formats were evaluated with a pHLA targeting TCR and the identical T cell recruiting antibody TCER® format had higher combination of potency and specificity2 than six alternative TCR Bispecific format designs evalu
Slide 44: TCER Format Designed for Optimized Efficacy and Safety: Tumor Control
TCER® Format Is Designed for Optimized Efficacy and Safety Superior Tumor Control Using a Novel, Low-Affinity Recruiter Widely used T cell recruiting Ab (3 variants) medium to high affinity (single to double digit nM) n = 6 mice/treatment group, n = 10 mice in vehicle group, 2 donors/group Dose: 0.0
Slide 45: TCER Format Designed for Optimized Efficacy and Safety: Cytokine Release
TCER® Format Is Designed for Optimized Efficacy and Safety Reduced Target-Unrelated Recruiter-Mediated Cytokine Release using a Low-Affinity Recruiter TCER® Whole blood cytokine release assay N=3 HLA-A*02-positive donors N=16 cytokines tested, 4 exemplary cytokines shown
Slide 46: Our TCER Portfolio
Our TCER® Portfolio Broad Pipeline of Next-Gen Half-Life Extended TCR Bispecifics TCER® PRAME peptide presented by HLA-A*02:01 Start of clinical trial in Aug 2023, first clinical data published in November 2024 IMA402 Potential for addressing different indications and large patient populations with
Slide 47: In Vivo Expressed TCER Molecules Targeting Cancer-specific pHLA Targets
In Vivo Expressed TCER® Molecules Targeting Cancer-specific pHLA Targets Combining Immatics’ Target and TCR Platforms with Moderna’s mRNA Technology Immatics Moderna Delivery of TCER® biologics through mRNA Proprietary cancer targets & TCR Bispecifics format mRNA-encoded TCER® molecule XPRESIDENT® t
Slide 48: TCER IMA401 Targeting MAGEA4/8
TCER® IMA401 Targeting MAGEA4/8
Slide 49: TCER IMA401 Targeting MAGEA4/8: Higher Target Density
TCER® IMA401 Targeting MAGEA4/8 Higher Target Density of MAGEA4/8 Peptide MAGEA4 protein detection in tumor samples (IHC) 1MAGEA4/8 target prevalences are based on TCGA and in-house data combined with a XPRESIDENT®-determined target individual MS-based mRNA expression threshold; qPCR-threshold for p
Slide 50: IMA401 – Assessment of Anti-Tumor Activity in vivo
TCER® IMA401 (MAGEA4/8) – Assessment of Anti-Tumor Activity in vivo Patient-Derived Tumor Model NSCLC adenocarcinoma: Male, Caucasian, age 58, no therapy prior to surgery Site of origin: lung, differentiation poor Date of surgery: 1987, Freiburg Medical Center Volume doubling time: 7.3 day Histology
Slide 51: Trial Design – IMA401-101 Phase 1a Dose Escalation
Trial Design – IMA401-101 Phase 1a Dose Escalation 180 µg 540 µg 1800 µg 2500 µg Key Eligibility Criteria Objectives Primary: Determine MTD and/or RP2D Secondary: Tolerability Pharmacokinetics Initial anti-tumor activity Recurrent and/or refractory solid tumors HLA-A*02:01 positive MAGEA4/8-positiv
Slide 52: Baseline Characteristics
Baseline Characteristics Heavily Pre-treated Patients with a Broad Range of Tumor Types 1Efficacy Analysis Set (EAS) prospectively defined in the study protocol: patients who received at least four IMA401 infusions and had at least one post-baseline efficacy assessment or clinical progression. Three
Slide 53: IMA401 Demonstrates Manageable Tolerability in N=35 Patients
IMA401 Demonstrates Manageable Tolerability in N=35 Patients Most Frequent Related AEs were Lymphopenia, CRS and Neutropenia TEAEs, n [%] All Grades ≥ Grade 3 Any 32 [91] 26 [74] Treatment-related 28 [80] 19 [54] Treatment-related AEs1, n [%] All Grades ≥ Grade 3 Lymphopenia 12 [34] 11 [31] Cytokine
Slide 54: IMA401 Pharmacokinetics
IMA401 Pharmacokinetics TCER® Format Shows Extended Half-Life in Solid Cancer Patients 1Half-lifes derived from 2nd PK profiles close to steady-state. Calculated by non-compartmental analysis (NCA) using Phoenix WinNonlin (Certara); Interquartile range (25%-75% percentile): 13.5-22.2 days; 2Data pre
Slide 55: Objective Responses are Associated with Target Expression
1Patients in this analysis had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression above indicated MAGEA4/A8high qPCR threshold (n=17); PD: Progressive disease; PR: Partial response; cPR: confirmed Partial response; SD: Stable disease. Objective Responses are Associated with Tar
Slide 56: IMA401 Demonstrates Initial Anti-Tumor Activity in Multiple Tumor Types
IMA401 Demonstrates Initial Anti-Tumor Activity in Multiple Tumor Types *Patients in this analysis are part of the efficacy analysis set with at least one post-treatment tumor assessment and had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression higher than the MAGEA4/8 qPCR th
Slide 57: Clinical Activity in Heavily Pre-Treated Cancer Patients
Clinical Activity in Heavily Pre-Treated Cancer Patients CT and MRI scans courtesy of treating physicians (Dr. Manik Chatterjee, University Hospital Wuerzburg and Dr. Max-Felix Häring, Eberhard Karls University Tuebingen); HNSCC: Head and neck squamous cell carcinoma; NET CUP: Neuroendocrine tumor-c
Slide 58: First-in-human Data of IMA401 TCER Targeting MAGEA4/8
First-in-human Data of IMA401 TCER® Targeting MAGEA4/8 Presentation at ESMO on September 16, 2024 Tolerability: Most common treatment-related AEs are low-grade CRS, transient lymphopenia and neutropenia Pharmacokinetics: Median terminal half-life of 16.9 days supporting potential further flexibility
Slide 59: TCER IMA402 Targeting PRAME
TCER® IMA402 Targeting PRAME
Slide 60: IMA402 – Efficacy Assessment in vitro
TCER® IMA402 Targeting PRAME – Efficacy Assessment in vitro Tumor Cell Killing at Low Physiological PRAME Peptide Levels TCER® IMA402 induces killing of tumor cells with PRAME target copies as low as 50 CpCs Physiological PRAME levels detected in majority of cancer tissues from patients are 100 – 10
Slide 61: IMA402 Achieves Dose-Dependent Durable Tumor Control in vivo
TCER® IMA402 Achieves Dose-Dependent Durable Tumor Control in vivo Dose-response Relationship in Mouse Xenograft Model 0.01 mg/kg mouse dose à equivalent to approximately 0.6 mg human dose (~DL5) 0.05 mg/kg mouse dose à equivalent to approximately 3 mg human dose (DL7) Data presented at ESMO 2022 Pr
Slide 62: Half-life Extended Format of IMA402 Confers Terminal Half-life of >1 Week
Half-life Extended Format of IMA402 Confers Terminal Half-life of >1 Week pHLA – aVL Assay pHLA – aFc Assay IMA402 shows a terminal serum half-life of ≈ 8 days in mice IMA402 will be initially dosed weekly in the clinical trial Dosing frequency may be adapted based on clinical data IMA402
Slide 63: Phase 1/2 Clinical Trial to Evaluate TCER IMA402 Targeting PRAME
Phase 1/2 Clinical Trial to Evaluate TCER® IMA402 Targeting PRAME Phase 1: Dose Escalation Phase 2a: Dose Expansion Adaptive design aimed at accelerating dose escalation Specific indications plus ongoing basket Combination therapies Optional dose/application optimization Expansion cohort Expansion c
Slide 64: Baseline Characteristics Heavily Pre-treated Patients
Baseline Characteristics Heavily Pre-treated Patients 1Efficacy Analysis Set prospectively defined in the study protocol: patients who received at least four IMA402 infusions and had at least one post-baseline efficacy assessment or clinical progression. LDH: Lactate dehydrogenase; ULN: Upper limit
Slide 65: IMA402 Demonstrates Favorable Tolerability in N=33 Patients
IMA402 Demonstrates Favorable Tolerability in N=33 Patients Most Frequent Related AEs were Lymphopenia and CRS TEAEs, n [%] All Grades ≥ Grade 3 Any 33 [100] 17 [52] Treatment-related 32 [97] 15 [45] Treatment-related AEs1, n [%] All Grades ≥ Grade 3 Lymphopenia 17 [52] 10 [30] Cytokine release synd
Slide 66: Early Signs of Clinical Activity Associated with PRAME Expression and IMA402 Dose
PRAME Status Negative Positive/NT Dose Levels Across DLs 1-6 7+* Patients with Tumor Shrinkage 14% 25% 78% Early Signs of Clinical Activity Associated with PRAME Expression and IMA402 Dose 66 BOR (RECIST 1.1) Ongoing response / SD (RECIST1.1/ iRECIST) Data cut-off Nov 6, 2024 * Patients who received
Slide 67: Exemplary Patient Cases Suggesting Dose-Dependent Tumor Response
Exemplary Patient Cases Suggesting Dose-Dependent Tumor Response Patients with Disease Control (RECIST1.1) at Relevant Doses (DL7+) Data cut-off Nov 6, 2024 BOR: Best Overall Response; SD: Stable Disease; cPR: Confirmed Partial Response; arrow: Ongoing response / stable disease (RECIST 1.1/ iRECIST)
Slide 68: IMA402 Phase 1 Dose Escalation Study Summary
IMA402 Phase 1 Dose Escalation Study Summary as of Nov 6, 2024 Data cut-off Nov 6, 2024 NT: not tested or not evaluable for PRAME expression; CRS: Cytokine release syndrome; DCR: Disease control rate For comprehensive patient flow chart, see appendix Study design and patient population BLRM-model ba
Slide 69: Immatics' Proprietary Target and TCR Discovery Platforms
Immatics’ Proprietary Target and TCR Discovery Platforms
Slide 70: Our TCR-based Approaches Leverage the Full Target Space
Our TCR-based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface Technology
Slide 71: True Cancer Targets & Matching Right TCRs
True Cancer Targets & Matching Right TCRs Goal to Maximize Anti-Tumor Activity and Minimize Safety Risks of TCR-based Immunotherapies True Targets via XPRESIDENT® technology platform are naturally presented on tumor tissues as identified by mass-spec are absent or presented at only low levels on nor
Slide 72: Pool of Prioritized Targets as Foundation for Future Value Generation
Technology Pool of 200 Prioritized Targets as Foundation for Future Value Generation XPRESIDENT® Target Platform 200 Prioritized Targets Grouped in 3 Target Classes: Well known and characterized parent protein (20%) e.g. MAGE family cancer testis antigens Unknown or poorly characterized parent prote
Slide 73: Potential for Large Patient Populations across Multiple Solid Cancers
Potential for Large Patient Populations across Multiple Solid Cancers Uterine Carcinoma – 97% Uterine Carcinosarcoma – 100% Sarcoma Subtypes – up to 100% Cut. Melanoma – 95% Uveal Melanoma1 – 89% Ovarian Carcinoma – 84% Squamous NSCLC – 68% TNBC – 63% Small Cell Lung Cancer – 45% Kidney Carcinoma –
Slide 74: Identification of the most Relevant Target
Immatics’ Unique Capability – Identification of the most Relevant Target Example of MAGEA4/8 Peptide Target 1 Copy number per tumor cell (CpC) measured on a paired-sample basis by AbsQuant®, i.e. comparing MAGEA4 vs. MAGEA4/A8 peptide presentation on same sample, 2 Students paired T test p<0.0012 Te
Slide 75: Development of the Right TCR – XCEPTOR Technology
Development of the Right TCR – XCEPTOR® Technology TCR Discovery and Engineering for ACT and TCR Bispecifics TCR Bispecifics T cell engaging receptor (TCER®) Adoptive Cell Therapy ACTengine® ACTallo® Fast, efficient and highly sensitive discovery of highly specific, natural TCRs Protein engineering
Slide 76: Optimal Target Selection & TCR Specificity for Minimizing Safety Risks
Optimal Target Selection & TCR Specificity for Minimizing Safety Risks Unique Interplay between Technology Platforms Allows Early De-risking for Clinical Development Target peptide presented on tumor cells Selective killing of tumor cells Target peptide presented on normal cells Off-target toxicity
Slide 77: Bioinformatics and AI-Platform XCUBE
“AI Is Where the Data Is®” Bioinformatics and AI-Platform XCUBE™ Data Engineering Development of data warehouses & user interfaces Data Science Development of statistical & machine learning models Data Processing Processing of mass-spec & next-gen sequencing data 1 THERAPEUTIC KNOWLEDGE XPRESIDENT®/
Slide 78: Immatics' Robust Intellectual Property Portfolio
Immatics’ Robust Intellectual Property Portfolio Protection Strategy of Key Assets in Major Markets and Beyond Technologies Targets TCRs TCER® Therapeutic Uses Cell Therapy TCRs with high affinity and specificity profile Differentiated technologies, platforms and assays for Target Research, TCR and
Slide 79: ACTengine IMA204 – TCR-T Targeting COL6A3 Exon 6
ACTengine® IMA204 – TCR-T Targeting COL6A3 Exon 6
Slide 80: ACTengine IMA204 First-in-Class TCR-T Targeting Tumor Stroma
ACTengine® IMA204 First-in-Class TCR-T Targeting Tumor Stroma Key Features HLA-A*02-presented peptide derived from COL6A3 exon 6 Naturally and specifically presented on tumors at high target density1: 100-700 copies/cell Novel tumor stroma target identified and validated by XPRESIDENT® quant. mass s
Slide 81: ACTengine IMA204 – High Affinity, CD8-independent TCR
ACTengine® IMA204 – High Affinity, CD8-independent TCR Complete Tumor Eradication in vitro & in vivo1 by Affinity-enhanced IMA204 TCR CD8-independent TCR leads to tumor eradication in all mice treated Control IMA204 TCR D7 D16 D22 D29 Affinity maturated CD8-independent, next-generation TCR engages b
Slide 82: ACTallo – Our Next-generation Off-the-shelf TCR-T
ACTallo® – Our Next-generation Off-the-shelf TCR-T
Slide 83: ACTallo – Immatics' Allogeneic Cell Therapy Approach
ACTallo® – Immatics’ Allogeneic Cell Therapy Approach Off-the-shelf cell therapy, no need for personalized manufacturing à reduced logistics and time to application Potential for hundreds of doses from one single donor leukapheresis à lower cost of goods Use of healthy donor material provides standa
Slide 84: Why γδ T cells?
Why γδ T cells? γδ T cells Are Well Suited for an Off-the-shelf Cell Therapy Approach γδ T cells are abundant in the peripheral blood show intrinsic anti-tumor activity naturally infiltrate solid tumors & correlate with favorable prognosis are HLA-independent, thus do not cause graft-vs-host disease
Slide 85: Corporate Information
ooe immiatics Corporate Information
Slide 86: Management Team
David Leitner Schuldirektor David Leitner Schuldirektor David Leitner Schuldirektor Harpreet Singh Chief Executive Officer Co-Founder >20 yrs biotech experience Arnd Christ Chief Financial Officer >20 yrs biotech experience (InflaRx, Medigene, NovImmune, Probiodrug) Carsten Reinhardt Chief Developme
Slide 87: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans-Atlantic Organization Houston, Texas ~205 FTEs Cell therapy development & manufacturing Munich, Germany ~85 FTEs Various operating functions Tübingen, Germany ~255 FTEs Target & TCR discovery and TCR Bispecifics development Corporate FTEs as of June 30, 20
Slide 88: Delivering the Power of T cells to Cancer Patients
Delivering the Power of T cells to Cancer Patients Appendix www.immatics.com 028 immatics
Slide 89: IMA402 Phase 1a Patient Population Flow Chart
IMA402 Phase 1a Patient Population Flow Chart Safety Population (N=33 enrolled patients) Efficacy-evaluable Population* (N=28 patients with ≥4 IMA402 infusions and ≥1 post-baseline scan) N=21 PRAME positive/ not tested or not evaluable patients N=2 patients did not receive assigned target dose N=3 p